Publications by authors named "Anna Angona"

Claim this Profile
C
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.
Dolly Viviana Fiallo-Suárez, Ruth Stuckey, Cristina Bilbao-Sieyro, María Tapia Torres, Leonor Pérez-Ortíz, Anna Angona

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.
Lucía Pérez-Lamas, Adrián Segura Diaz, Regina García Delgado, Alberto Álvarez-Larrán, María Alicia Senin, Anna Angona

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.
Marta Santaliestra, Marta Garrote, María Soledad Noya, Manuel Pérez-Encinas, Alicia Senín, Anna Angona

Leukemia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.
Irene Pastor-Galán, Arturo Pereira, Eduardo Arellano-Rodrigo, Iván Martín, Adrián Mosquera-Orgueira, Anna Angona

Leukemia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
Lucía Pérez-Lamas, Adrián Segura Díaz, Elvira Mora Casterá, Marta Hidalgo Soto, Antonio Paz Coll, Anna Angona

Ann Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Alberto Hernández-Sánchez, Ángela Villaverde-Ramiro, Eduardo Arellano-Rodrigo, Marta Garrote, Iván Martín, Anna Angona

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
Adrián Mosquera-Orgueira, Eduardo Arellano-Rodrigo, Marta Garrote, Iván Martín, Manuel Pérez-Encinas, Anna Angona

Hemasphere· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Sílvia Marcé, Aleix Méndez, Blanca Xicoy, Natalia Estrada, Marta Cabezón, Anna Angona

J Clin Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
Alberto Alvarez-Larrán, Beatriz Cuevas, Patricia Velez, Soledad Noya, Gonzalo Caballero-Navarro, Anna Angona

Hemasphere· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Anna Angona

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, Alberto Hernández-Sánchez, Teresa González-Martínez, Eduardo Arellano-Rodrigo, Anna Angona

Hemasphere· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Johana Díaz-Santa, Rocío Rodríguez-Romanos, Rosa Coll, Gemma Osca, Marta Pratcorona, Anna Angona

Eur J Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Anna Angona

Am J Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Ana Triguero, Alexandra Pedraza, Manuel Perez-Encinas, María Isabel Mata-Vazquez, Patricia Vélez, Anna Angona

Ann Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Juan-Carlos Hernández-Boluda, Irene Pastor-Galán, Eduardo Arellano-Rodrigo, José-María Raya, Manuel Pérez-Encinas, Anna Angona

Br J Haematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough infections in MPN-COVID vaccinated patients.
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Anna Angona

Blood Cancer J· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Ana Triguero, Alexandra Pedraza, Manuel Pérez-Encinas, María Isabel Mata-Vázquez, Patricia Vélez, Anna Angona

Ann Hematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alberto Alvarez-Larrán, Marta Garrote, Francisca Ferrer-Marín, Manuel Pérez-Encinas, M Isabel Mata-Vazquez, Anna Angona

Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.
María García-Fortes, Juan C Hernández-Boluda, Alberto Álvarez-Larrán, José M Raya, Anna Angona

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second versus first wave of COVID-19 in patients with MPN.
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Anna Angona

Leukemia· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Sílvia Marcé, Blanca Xicoy, Olga García, Marta Cabezón, Natalia Estrada, Anna Angona

J Clin Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of recovered MPN patients with COVID-19.
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Anna Angona

Blood Cancer J· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Anna Angona

Leukemia· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Valentín Garcia-Gutiérrez, Alejandro Luna, Juan M Alonso-Dominguez, Natalia Estrada, Concepcion Boque, Anna Angona

Blood Cancer J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Anna Angona

Blood Cancer J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis